Literature DB >> 27543916

Reliability of a patient-reported outcome measure in schizophrenia: Results from back-to-back self-ratings.

Hiroyoshi Takeuchi1, Gagan Fervaha2, Gary Remington3.   

Abstract

This study aimed to assess patient's capacity to perform a patient-reported outcome (PRO) measure (i.e., a self-rating scale) and examine its relationship with clinical characteristics including cognition. Fifty patients with schizophrenia were asked to rate the Subjective Well-being under Neuroleptics scale - Short form (SWNS) twice; the second rating was started immediately after they completed the first to minimize the gap between ratings. At the same time, the Positive and Negative Symptoms Scale (PANSS) and Brief Neurocognitive Assessment (BNA) were administered. The correlations between the two ratings for the SWNS total and each item scores were high (rs=0.94 and rs=0.60-0.84, respectively); however, for 16 (80%) of 20 items, 5 or more patients (i.e., ≥10%) demonstrated a>1 point score difference. There was no significant correlation between the SWNS total score difference and any clinical characteristics including age, education duration, illness duration, antipsychotic dose, psychopathology, and cognition. In contrast, the number of items with a>1 point score difference was significantly correlated with disorganized symptoms and overall severity (rs=0.29 for both), as well as working memory and global cognition (rs=-0.41 and rs=-0.40, respectively). These findings suggest that PROs should be interpreted with caution in patients with schizophrenia with prominent disorganization and cognitive impairment.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cognition; Patient-reported outcome measures; Reliability; Schizophrenia; Self-rating; Subjective well-being

Mesh:

Substances:

Year:  2016        PMID: 27543916     DOI: 10.1016/j.psychres.2016.07.055

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

Review 1.  A meta-analytic review of self-reported, clinician-rated, and performance-based motivation measures in schizophrenia: Are we measuring the same "stuff"?

Authors:  Lauren Luther; Ruth L Firmin; Paul H Lysaker; Kyle S Minor; Michelle P Salyers
Journal:  Clin Psychol Rev       Date:  2018-04-07

2.  Commentary. Toward a core outcomes assessment set for clinical high risk.

Authors:  Scott W Woods; Catalina V Mourgues-Codern; Albert R Powers
Journal:  Schizophr Res       Date:  2020-05-12       Impact factor: 4.939

3.  Reliability of the Glasgow Antipsychotic Side-effects Scale for Clozapine Japanese version (GASS-C-J).

Authors:  Kohei Kitagawa; Ryuhei So; Nobuyuki Nomura; Yuya Mizuno; Fuminari Misawa; Masafumi Kodama; Hiroyuki Uchida; Masaru Mimura; Hiroyoshi Takeuchi
Journal:  PLoS One       Date:  2020-06-18       Impact factor: 3.240

4.  Measuring the Burden of Schizophrenia Using Clinician and Patient-Reported Measures: An Exploratory Analysis of Construct Validity.

Authors:  Matthew Franklin; Clara Mukuria; Brendan Mulhern; Irwin Tran; John Brazier; Stuart Watson
Journal:  Patient       Date:  2019-08       Impact factor: 3.883

5.  Applying machine learning to smartphone based cognitive and sleep assessments in schizophrenia.

Authors:  Mark Kalinich; Senan Ebrahim; Ryan Hays; Jennifer Melcher; Aditya Vaidyam; John Torous
Journal:  Schizophr Res Cogn       Date:  2021-10-01

6.  Ginkgo biloba induced mood dysregulation: a case report.

Authors:  Seung Sun Rho; Young Sup Woo; Won-Myong Bahk
Journal:  BMC Complement Altern Med       Date:  2018-01-15       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.